Interview with Christian Schilling, CEO, Boehringer Ingelheim Austria
Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first…
Address: ‘Dr.-Boehringer-Gasse 5-11
A-1121 Wien’
,Austria
Tel: (+43 1) 80 105-0
Web: http://www.boehringer-ingelheim.at/
Boehringer Ingelheim – one of the world‘s 20 leading pharmaceutical companies
The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
For more information please visit www.boehringer-ingelheim.com
Boehringer Ingelheim in Austria
Boehringer Ingelheim founded its first subsidiary outside Germany in a Viennese pharmacy in 1948. From these modest beginnings, the Austrian company has developed into a modern high technology concern.
Today the company is of great importance as a cancer research centre and one of the three biopharmaceutical research, development and production centres in the international group. As the Regional Center Vienna it is responsible for the pharmaceutical business (human pharmaceuticals and animal health) and for clinical trials in more than 30 countries in Central and Eastern Europe (including Austria).
Over the last years Boehringer Ingelheim has created 530 new jobs in Vienna and invested around 360 million euros in the Vienna site.
Activities of the Boehringer Ingelheim Regional Center Vienna
• Business responsiblity for Boehringer Ingelheim products in more than 30 countries of Central and Eastern Europa – Human Pharmaceuticals and Animal Health
• International Oncology Research Center
• Clinical Research in all therapeutic areas of the Corporation in Central and Eastern Europe (including Austria and Switzerland), Turkey, South Africa and Israel
• Biopharmaceutical research, development and production
Boehringer Ingelheim Regional Center Vienna
The Regional Center Vienna (RCV) is responsible for the human pharmaceuticals (prescription medicines and over-the-counter products) and animal health business in more than 30 Central and Eastern European countries. Moreover the whole clinical research of the region is managed by the RCV. Vienna is the oncology research center and a center of biopharmaceutical research, development and production in the international group of companies. Boehringer Ingelheim is also engaged in basic research, represented by the Research Institute of Molecular Pathology (IMP) in Vienna. Therefore BI is one of the most research focused pharmaceutical companies in Austria. In 2011 the Boehringer Ingelheim Regional Center Vienna earned 736,2 million euros and had about 3,000 employees in Austria and Eastern Europe.
Animal Health
International Research Center of Oncology
Clinical research in all therapeutic areas of the business association – studies in 15 countries of Central and Eastern Europe (including Austria)
Biopharmaceutical development and manufacturing of pharmaceuticals
Austria has always been a strategic market for the group: it has played a key role in Boehringer Ingelheim’s success story, as this is where the company established its first…
Dr. Wolfgang Schnitzel, general manager of Shire Austria, and Karl-Heinz Hofbauer, site lead Vienna and managing director for the Technical Operations business, discuss the huge impact of Shire’s 32 billion…
Maria Seriakov, CEO and founder of M bioserviceS, a young Austrian company dealing globally that specialises in logistics, regulatory affairs and quality control of biologics, discusses the challenges of navigating…
Prof. Ruth Ladenstein, executive director of the Medicines for Children Research Organisation (OKIDS) in Austria, explains OKIDS’ drive to ensure drugs are paediatric specific by conducting child-specific clinical trials. Furthermore,…
Philipp Lindinger, managing director of Austromed, the Austrian association for medical devices and in-vitro diagnostics, discusses the organization’s purpose, the impact of European regulation on medical devices on the sector,…
Martin Prinz, CTO of Croma-Pharma, a family-owned Austrian aesthetic dermatology company, discusses the evolution of the company over the years and their specialist, ever-expanding portfolio. Additionally, he documents the role…
Mario Huber, general manager of PharmaMar Austria, a multinational and an innovative oncology-based Spanish company, discusses the growth of the company in Austria and the reasons behind the success of…
Michael Stampfer, managing director of the Vienna Science and Technology Fund (WWTF), the only private, non-profit organization in Vienna dedicated to funding scientific research, discusses the challenges scientific research faces…
Michaela Latzelsberger, country manager of Coloplast Austria, a Danish medical device company focused on ostomy, continence and wound care, discusses the challenges of launching innovative medical devices on the Austrian…
Urs Weber, general secretary of the Swiss Chamber of Commerce in Austria, discusses the role of the chamber as a networking facilitator between Austrian and Swiss companies as well as…
Heidrun Katholnigg, executive director of global clinical development Europe for Celerion, a global CRO that specialises in phase I, II and III clinical trials, discusses the acquisition of Assign Group…
Ulrich Schlick, deputy managing director of the German Chamber of Commerce in Austria, discusses the Chamber’s role in facilitating business opportunities for German companies in Austria and vice versa. He…
Bernd Grabner, board member of Jacoby GM pharma, a leading Austrian wholesaler, provides an in-depth look into the historical merger of family owned Jacoby, GM pharma and Kӧgl Pharma as…
See our Cookie Privacy Policy Here